Follow
Sha Cao
Sha Cao
Verified email at imbim.uu.se
Title
Cited by
Cited by
Year
Selection of resistant bacteria at very low antibiotic concentrations
E Gullberg, S Cao, OG Berg, C Ilbäck, L Sandegren, D Hughes, ...
PLoS pathogens 7 (7), e1002158, 2011
14272011
In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii
M Juhas, E Widlake, J Teo, DL Huseby, JM Tyrrell, YS Polikanov, O Ercan, ...
Journal of Antimicrobial Chemotherapy 74 (4), 944-952, 2019
572019
FimH alleles direct preferential binding of Salmonella to distinct mammalian cells or to avian cells
A Guo, S Cao, L Tu, P Chen, C Zhang, A Jia, W Yang, Z Liu, H Chen, ...
Microbiology 155 (5), 1623-1633, 2009
502009
A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants
DD Khan, P Lagerbäck, S Cao, U Lustig, EI Nielsen, O Cars, D Hughes, ...
Journal of Antimicrobial Chemotherapy 70 (11), 3051-3060, 2015
422015
Alternative Evolutionary Pathways for Drug-Resistant Small Colony Variant Mutants in Staphylococcus aureus
S Cao, DL Huseby, G Brandis, D Hughes
MBio 8 (3), e00358-17, 2017
382017
Can phylogenetic type predict resistance development?
H Nazir, S Cao, F Hasan, D Hughes
Journal of antimicrobial chemotherapy 66 (4), 778-787, 2011
342011
Ilbä ck C, Sandegren L, Hughes D, et al. Selection of resistant bacteria at very low antibiotic concentrations
E Gullberg, S Cao, OG Berg
PLoS Pathog 7 (7), e1002158, 2011
312011
Genetic complexity of fusidic acid-resistant small colony variants (SCV) in Staphylococcus aureus
J Lannergård, S Cao, T Norström, A Delgado, JE Gustafson, D Hughes
PloS one 6 (11), e28366, 2011
282011
Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data
EI Nielsen, DD Khan, S Cao, U Lustig, D Hughes, DI Andersson, ...
Journal of Antimicrobial Chemotherapy 72 (11), 3108-3116, 2017
232017
Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination
S Cao, A Guo, Z Liu, Y Tan, G Wu, C Zhang, Y Zhao, H Chen
Infection and immunity 77 (10), 4679-4687, 2009
232009
A chimeric protein that functions as both an anthrax dual-target antitoxin and a trivalent vaccine
G Wu, Y Hong, A Guo, C Feng, S Cao, CC Zhang, R Shi, Y Tan, Z Liu
Antimicrobial agents and chemotherapy 54 (11), 4750-4757, 2010
172010
Efficient production and characterization of Bacillus anthracis lethal factor and a novel inactive mutant rLFm-Y236F
S Cao, Z Liu, A Guo, Y Li, C Zhang, W Gaobing, F Chunfang, Y Tan, ...
Protein expression and purification 59 (1), 25-30, 2008
162008
Soluble expression and purification of the anthrax protective antigen in E. coli and identification of a novel dominant-negative mutant N435C
G Wu, C Feng, Y Hong, A Guo, S Cao, J Dong, L Lin, Z Liu
Applied microbiology and biotechnology 87 (2), 609-616, 2010
152010
Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
T Sou, J Hansen, E Liepinsh, M Backlund, O Ercan, S Grinberga, S Cao, ...
Clinical Pharmacology & Therapeutics 109 (4), 1063-1073, 2021
142021
Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB)
M De Rosa, L Lu, E Zamaratski, N Szałaj, S Cao, H Wadensten, ...
Bioorganic & Medicinal Chemistry 25 (3), 897-911, 2017
132017
Co‐evolution with recombination affects the stability of mobile genetic element insertions within gene families of Salmonella
G Brandis, S Cao, D Hughes
Molecular Microbiology 108 (6), 697-710, 2018
122018
Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice
K Becker, V Aranzana-Climent, S Cao, A Nilsson, R Shariatgorji, ...
Clinical Microbiology and Infection 27 (9), 1315-1321, 2021
112021
Having your cake and eating it-Staphylococcus aureus small colony variants can evolve faster growth rate without losing their antibiotic resistance
G Brandis, S Cao, DL Huseby, D Hughes
Microbial cell 4 (8), 275, 2017
112017
Boronic ester-linked macrocyclic lipopeptides as serine protease inhibitors targeting Escherichia coli type I signal peptidase
N Szałaj, L Lu, A Benediktsdottir, E Zamaratski, S Cao, G Olanders, ...
European Journal of Medicinal Chemistry 157, 1346-1360, 2018
102018
Imidazopyrazinones (IPYs): non-quinolone bacterial topoisomerase inhibitors showing partial cross-resistance with quinolones
F Jeannot, T Taillier, P Despeyroux, S Renard, A Rey, M Mourez, ...
Journal of Medicinal Chemistry 61 (8), 3565-3581, 2018
102018
The system can't perform the operation now. Try again later.
Articles 1–20